BICO - The Bio Convergence Company WKN: A2PX00 ISIN: SE0013647385 Forum: Aktien User: Support

BICO provides preliminary figures for Q3 2025, full report released, tomorrow, November 4 Sales is expected to amount to SEK 387m (369), corresponding to an organic sales growth of 12 percent Adjusted EBITDA is expected to amount to SEK 17m (6), corresponding to an adjusted EBITDA margin of 5 percent, which is an improvement in the adjusted EBITDA-margin of around 3 percentage points YoY BICO showed organic sales growth in both business areas Lab Automation (35 percent YoY) and Life Science Solutions (4 percent YoY), despite macro-economic headwinds BICO has concluded impairments in Discover ECHO and Biosero totaling SEK 1,036m. These impairments will not affect cash flow, but will impact EBIT for Q3 2025 In May 2024, BICO adopted an impairment model, which shortened the forecast period before terminal value from ten to five years, following recommendation from the Swedish Financial Reporting Supervision. The impairments stem from a short forecast period and lower year-to-date trading in 2025 leading to changed forecast assumptions compared with previous periods BICO anticipates long-term growth of around 10 percent CAGR, which is in line with our financial targets. The company also reaffirms strong underlying demand for Biosero’s integrated lab automation solutions and Biosero’s market-leading software suite Green Button Go Impairments per Q3 2025 BICO has resolved goodwill impairment in Discover ECHO SEK 471m and Biosero SEK 539m totaling SEK 1,010m. In addition, impairment of trademarks and technology of SEK 26m has been concluded in Discover ECHO. These impairments will not affect cash flow but will impact EBIT for Q3 2025. In May 2024, BICO adopted an impairment model, which shortened the forecast period from ten to five years, following recommendation from the Swedish Financial Reporting Supervision. Discover Echo’s financial development has been weaker than previously forecasted, mainly as a result of reduced financing from National Institute of Health (NIH), which has impacted the demand in the academic customer segment. As a result, the revised sales and cash forecasts, reflecting the continued softness in academic research funding which has had an impact on the goodwill value For Biosero, BICO sees a strong underlying demand for integrated lab automation solutions and Biosero’s market-leading software suite Green Button Go. However, a short forecast period and lower year-to-date trading in 2025 are leading to changed forecast assumptions compared with previous periods which have an impact on the goodwill Preliminary figures Q3 2025 The net sales for Q3 is expected to amount to SEK 387m (369) and the organic sales growth is expected to amount to 12 percent (-18). The EBITDA for Q3 is expected to amount to SEK 5m (4), corresponding to a margin of 1 percent (1). The adjusted EBITDA for Q3 is expected to amount to SEK 17m (6) corresponding to a margin of 5 percent (2). The cash flow from operating activities for Q3 is expected to amount to SEK -32m (45), the cash flow from investing activities for Q3 is expected to amount to SEK 716m (-27) and the cash flow from financing activities for Q3 is expected to amount to SEK -115m (-18). Group’s cash and cash equivalents on September 30, 2025, amounted to SEK 1,241m.

Nie! 🍟 Bude

In 10 Jahren vlt

Wann geht es wieder auf 30 ?

Habe es die ganze Zeit gesagt

Insolvenz

Du vermutlich?

Insolvenz

Nix

Was gerade los hier?

Ok - dann kannst jetzt einsteigen 👍

Unter 3 steige ich hier ein

😱